Related content

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults

By Hentig Nils   Dauer Brenda   Haberl Annette   Klauke Stefan   Lutz Thomas   Staszewski Schlomo   Harder Sebastian  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 10, 2007-10 ,pp. : 935-940

Springer Publishing Company

Access to resources Recommend Favorite

Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients

By Sriwiriyajan Somchai   Mahatthanatrakul Werawath   Ridtitid Wibool   Jaruratanasirikul Sutep  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 5, 2007-05 ,pp. : 479-483

Springer Publishing Company

Access to resources Recommend Favorite

Ritonavir-boosted darunavir: a powerful option for treatment-experienced HIV-1-infected patients

By Menééndez-Arias Luis   Matamoros Tania   ÁÁlvarez Mar  

Future Virology, Vol. 3, Iss. 5, 2008-09 ,pp. : 423-434

Future Medicine

Access to resources Recommend Favorite

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients

By Elens Laure   Vandercam Bernard   Yombi Jean-Cyr   Lison Dominique   Wallemacq Pierre   Haufroid Vincent  

Pharmacogenomics, Vol. 11, Iss. 9, 2010-09 ,pp. : 1223-1234

Future Medicine

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Low Dose Mycophenolate Mofetil in HIV-Infected Patients Treated with Abacavir, Efavirenz and Nelfinavir

By Millán Olga  

Clinical Pharmacokinetics, Vol. 44, Iss. 5, 2005-01 ,pp. : 525-538

Adis International

Access to resources Recommend Favorite